Get started
Work

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Year: 2024
Type: erratum
Abstract: Correction to: npj Breast Cancer (2022) 8 :98; https://doi.org/10.1038/s41523-022-00467-1 , published online 29 August 2022
DOI: 10.1038/s41523-024-00650-6
Authors: Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Institut Curie, Universitair Ziekenhuis Leuven, Harvard University, Massachusetts General Hospital, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Baylor University Medical Center, Vall d'Hebron Institute of Oncology, Universidad Europea de Madrid, Centre Eugène Marquis, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Institut Jules Bordet, Immunomedics (United States), Emory University, Columbia University Irving Medical Center, Winship Cancer Institute
Language: English
Subfield: Cancer Research
Open Access status: gold
Estimated APC paid: $3,490
OpenAlex ID: W4399385737
Cites:
Cited by:
Related to: 10